APA (7th ed.) Citation

A, A., KD, J., MB, H., P, H., H, H., C, W., . . . D, R. (2026). Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021). Current oncology (Toronto, Ont.), 33(5), . https://doi.org/10.3390/curroncol33050289

Chicago Style (17th ed.) Citation

A, Aleksi, Jobin KD, Hannouf MB, Husi P, Halperin H, White-Gloria C, Abedin T, and Ruether D. "Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021)." Current Oncology (Toronto, Ont.) 33, no. 5 (2026). https://doi.org/10.3390/curroncol33050289.

MLA (9th ed.) Citation

A, Aleksi, et al. "Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021)." Current Oncology (Toronto, Ont.), vol. 33, no. 5, 2026, https://doi.org/10.3390/curroncol33050289.